Sorafenib is effective in the treatment of pulmonary veno-occlusive disease

Masaharu Kataoka, Ryoji Yanagisawa, Keiichi Fukuda, Hideaki Yoshino, Toru Satoh

研究成果: Article査読

13 被引用数 (Scopus)

抄録

The present study is the first report of the effectiveness of sorafenib in the treatment of pulmonary veno-occlusive disease (PVOD). A 66-year-old woman with PVOD was started on sorafenib. After 3 months of treatment with a maximum dosage of 400 mg/day sorafenib, there was an improvement in the patient's New York Heart Association (NYHA) functional class from IV to III. However, because of severe painful eruptions as a side effect of sorafenib, the patient stopped sorafenib and was started on imatinib instead. This treatment resulted in a worsening of the patient's NYHA class from III to IV, so sorafenib was restarted at a reduced dosage of 300 mg/day. The resumption of sorafenib was associated with clinical improvement, specifically NYHA class from IV to II and hemodynamic amelioration, and tolerable eruptions. In conclusion, sorafenib may be a potential therapeutic strategy for the treatment of PVOD.

本文言語English
ページ(範囲)172-174
ページ数3
ジャーナルCardiology (Switzerland)
123
3
DOI
出版ステータスPublished - 2012 11月
外部発表はい

ASJC Scopus subject areas

  • 循環器および心血管医学
  • 薬理学(医学)

フィンガープリント

「Sorafenib is effective in the treatment of pulmonary veno-occlusive disease」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル